BioSpace News Archive

Business

Money on the Move: EnPlusOne, Cellarity, Voyager and More

Funding rounds this week saw money flow into innovative drug discovery and delivery platforms, while pharma powerhouse Pfizer wrapped up two high-value neuro deals.

October 5, 2022
·
5 min read
·
Tristan Manalac
Drug Development

GSK’s Jemperli Stands Up in Phase II NSCLC Trial

GSK reported Wednesday its checkpoint inhibitor Jemperli yielded positive data in non-small cell lung cancer, moving the monoclonal antibody potentially closer to the market in this indication.

October 5, 2022
·
1 min read
·
Paul Elias
Business

Biohaven Sets New Course Following Pfizer Acquisition (Updated)

Biohaven will focus on developing therapeutics that modulate the Kv7 Ion Channel for the treatment of neurological and neuropsychiatric diseases. The new entity launched with $257.8 million in cash.

October 5, 2022
·
4 min read
·
Alex Keown
Business

TrialSpark and Sanofi Ink Six-Drug Deal Targeting Areas with High Unmet Need (Updated)

TrialSpark and Sanofi announced a new partnership to expedite drug development for areas with high unmet needs by licensing or acquiring six mid-to-late-stage drug candidates.

October 5, 2022
·
3 min read
·
Alex Keown
Business

OncoSec Slashes Headcount by Almost Half, Goes All-In on Lead Candidate

OncoSec Medical Inc. announced Tuesday that it was laying off around 45% of its workforce to focus its resources on the development of its lead asset TAVO-EP.

October 5, 2022
·
2 min read
·
Tristan Manalac
Amylyx Seeks Funding through Public Offering for Relyvrio Drug Launch

Amylyx plans to offer 6 million shares in a public offering to bring in between $167 to $192.2 million to support the manufacturing and commercialization of recently approved ALS drug Relyvrio.

October 5, 2022
·
3 min read
·
Mark Terry
Business

Nested Therapeutics Raises $90M to Crack New Proteins in Precision Oncology

Nested Therapeutics, a precision oncology company targeting previously undruggable cancer targets, closed on a $90 million Series A financing, bringing total financing to $125 million since its inception in 2021.

October 5, 2022
·
3 min read
·
Mark Terry
Genetown

ONWARD Announces Topline Results from the LIFT Home Study Supporting Safety and Feasibility of ARC-EX Therapy to Treat People with Spinal Cord Injury at Home

ONWARD Medical N.V. reported topline results from the LIFT Home study, evaluating the safety and feasibility of ARC-EX Therapy when used at home.

October 5, 2022
·
6 min read
Biotech Beach

SpineX Demonstrates Groundbreaking Technology to Treat Children with Cerebral Palsy

SpineX, Inc., a clinical stage medtech company announced the groundbreaking results its first in human study in children with cerebral palsy.

October 5, 2022
·
3 min read
Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies

Prokarium Ltd, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, announced the receipt of a Notice of Allowance from the United States Patent and Trademark Office.

October 5, 2022
·
2 min read